Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$1.11 USD
+0.05 (4.72%)
Updated Mar 31, 2023 04:00 PM ET
After-Market: $1.13 +0.02 (1.80%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
BNGO 1.11 +0.05(4.72%)
Will BNGO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BNGO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNGO
Bionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates
Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know
BNGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Bionano Genomics, Inc. (BNGO) to Report a Decline in Earnings: What to Look Out for
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?
Other News for BNGO
Bionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females
Bionano:1st study with OGM to identify SVs that may cause MRKH syndrome
Bionano launches optical genome mapping tests for prenatal, postnatal analysis
Bionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis
Bionano Genomics expands clinical testing menu with launch of two LDTs